CBD for Eczema and Skin Inflammation: What Works? | PureCraft CBD

Medical Disclaimer |  This article is for informational and educational purposes only and does not constitute medical advice. Eczema, psoriasis, and other inflammatory skin conditions require professional dermatological evaluation and management. CBD topical and oral products are not FDA-approved treatments for any skin condition and should not replace prescribed medications, dermatologist care, or trigger avoidance strategies. For moderate-to-severe skin conditions significantly affecting quality of life, physician or dermatologist evaluation is strongly encouraged. PureCraft CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.

 

The Skin Has Its Own Endocannabinoid System — and That Changes Everything

The skin is not just a passive barrier. It is the body's largest organ and a neurologically and immunologically active tissue that maintains its own endocannabinoid system — with CB1 and CB2 receptors expressed throughout keratinocytes, sebaceous glands, hair follicles, mast cells, Langerhans cells, and the sensory nerve endings that innervate the skin. The skin's ECS regulates key biological processes: sebum production, keratinocyte proliferation and differentiation, immune response modulation, barrier function, and the itch-pain signaling that makes inflammatory skin conditions so debilitating.

 

This skin-specific ECS is not a peripheral effect of a system designed for the brain. It is a locally operating regulatory network that manages the skin's own homeostasis. When this system is disrupted — by genetic factors, environmental triggers, or chronic inflammation — the result is the range of inflammatory skin conditions that CBD is increasingly being studied for. For the foundational ECS science, seeWhat Is the Endocannabinoid System? A Complete Guide.

 

This post covers the six most common inflammatory skin conditions and CBD's specific mechanisms for each. It is a supporting post in PureCraft's Conditions cluster. For the broader anti-inflammatory mechanisms that underpin the skin applications covered here, see theCBD for Arthritis Pillar(which covers CB2, TRPV1, and FAAH mechanisms in depth) andCBD for Neuropathy (which covers TRPV1 desensitization for itch/pain signaling).

 

The Cutaneous ECS: How the Skin Regulates Itself Through Cannabinoid Receptors

A landmark2009 review in Trends in Pharmacological Sciencesby Bíró et al. — titled 'The endocannabinoid system of the skin in health and disease' — established that the cutaneous ECS is a 'sophisticated' and essential regulatory network for skin homeostasis, and that its dysregulation contributes to multiple skin diseases. The key findings:

 

 

The clinical relevance:inflammatory skin diseases consistently show disrupted cutaneous ECS function. Atopic dermatitis patients have reduced CB1 expression in skin biopsies. Psoriatic plaques show altered CB2 expression. CBD — by inhibiting FAAH (preserving skin anandamide), activating CB1/CB2, and desensitizing TRPV1 — directly engages the regulatory system that inflammatory skin conditions have disrupted.

 

Six Skin Conditions and CBD's Mechanism for Each

 

 

Condition	Primary Driver	CBD Mechanism	Evidence Level	Format	Key Limitation
Atopic dermatitis (eczema)	Filaggrin gene mutations disrupt skin barrier allowing allergen penetration; Th2-dominant immune response producing IL-4, IL-13, IL-31; mast cell and IgE involvement; chronic itch-scratch cycle maintains inflammation	CB1/CB2 on keratinocytes and immune cells reduce Th2 cytokine production; TRPV1 desensitization reduces itch signaling (IL-31 drives itch via TRPV1-adjacent pathways); barrier repair support via ECS-mediated ceramide and lipid regulation	Moderate — 2019 Journal of Dermatological Treatment RCT positive; multiple observational studies; mechanism well-characterized in skin	Topical primary; oral CBD for stress/sleep component (stress triggers eczema flares through HPA → mast cell axis)	Does not address IgE-mediated allergic component or filaggrin structural defect; triggers must still be avoided
Psoriasis	T-cell mediated autoimmune hyperproliferation of keratinocytes; IL-17, IL-23 driven; keratinocytes proliferate 4–7× faster than normal producing plaques; TNF-α amplifies the cycle	CB1 agonism reduces keratinocyte hyperproliferation; CB2 reduces T-cell activation and cytokine production; anti-proliferative effects on keratinocytes documented in vitro	Moderate — in vitro and preclinical evidence strong; human RCT data limited; CBD topical and oral both relevant	Both topical (for plaque lesions) and oral CBD (systemic T-cell and cytokine modulation)	IL-17/IL-23 pathway not CBD's strongest target; moderate-severe psoriasis requires physician-directed treatment (biologics, DMARDs)
Contact dermatitis (allergic or irritant)	Allergic type: T-cell mediated hypersensitivity to hapten-allergen; Irritant type: direct epithelial damage from chemicals/detergents triggering innate immune response; both produce acute inflammation	CB2 on skin immune cells reduces the inflammatory cascade; TRPV1 desensitization reduces irritant pain/itch; anti-inflammatory cytokine profile shifts toward anti-inflammatory mediators	Emerging — mechanism well-supported; no contact dermatitis-specific CBD RCT; predominantly topical application relevant	Topical primarily — systemic CBD less relevant for acute contact dermatitis	Avoidance of trigger is primary intervention; CBD addresses symptom inflammation not the trigger sensitivity
Seborrheic dermatitis (scalp flaking, dandruff)	Malassezia yeast overgrowth triggering immune response on sebaceous-rich skin; sebum production dysregulation; IL-6, TNF-α involvement in scalp inflammation	CBD's sebostatic (sebum-reducing) effect via CB2 on sebaceous glands is the most directly relevant mechanism; anti-inflammatory CB2 action on scalp immune response	Moderate — 2014 Journal of Clinical Investigation study confirmed CBD's sebostatic effect; scalp application feasibility supported	Topical to scalp area; CBD-infused carrier oils appropriate for scalp use	Malassezia requires antifungal treatment if severe; CBD addresses sebum component, not fungal cause
Acne vulgaris	Sebum overproduction feeding Propionibacterium acnes proliferation; P. acnes triggers innate immune TLR2 response producing IL-1β, IL-8, TNF-α; hormonal androgen stimulation of sebaceous glands	CBD's sebostatic effect (most directly relevant for acne); anti-inflammatory suppression of IL-1β and TNF-α in sebaceous glands; antimicrobial properties against P. acnes documented in vitro	Moderate — 2014 JCI study established CBD's sebostatic mechanism; 2020 clinical study with CBD facial cream showed improvement; mechanism well-supported	Topical to face/affected area; oral CBD for stress-driven hormonal acne (stress → cortisol → androgen → sebum increase)	Does not address antibiotic-resistant P. acnes; moderate-severe acne requires physician care; hormonal acne needs hormonal management
Rosacea	Vascular dysregulation producing flushing; Th1-mediated inflammation; cathelicidin (LL-37) overexpression triggering inflammatory cascade; Demodex mite involvement in some cases; sensitive skin barrier	Anti-inflammatory CB2 mechanism relevant; possible vascular calming via ECS-mediated vasodilation/constriction modulation; TRPV1 desensitization for redness and sensitivity	Emerging — no rosacea-specific CBD RCT; mechanism moderately supported; observational reports positive for redness/sensitivity reduction	Topical only — gentle, fragrance-free formulation essential for rosacea-sensitive skin	Vascular and Demodex components require dermatologist management for moderate-severe rosacea; CBD addresses inflammatory component

 

 

The most important pattern in this table:Atopic dermatitis and acne have the best human evidence base for CBD; psoriasis has the strongest mechanistic case for systemic oral CBD; and all six conditions benefit primarily from topical CBD application for the local inflammatory component. The oral CBD route adds value when the skin condition has a significant systemic or stress-driven component — particularly for eczema (stress triggers flares through the HPA-mast cell axis) and psoriasis (systemic T-cell dysregulation).

 

CBD's Sebostatic Effect: The Mechanism Behind the Acne and Seborrheic Results

One of CBD's most specifically documented skin mechanisms is its sebostatic effect — the ability to reduce sebum (skin oil) production from sebaceous glands. Alandmark 2014 study in the Journal of Clinical Investigation by Oláh et al. systematically examined CBD's effects on human sebocyte cultures and found that CBD: (1) significantly inhibited excessive sebum production; (2) had potent anti-inflammatory effects on sebocytes, suppressing pro-inflammatory cytokine production; and (3) did not interfere with normal sebocyte homeostasis at physiological anandamide levels. The mechanism involves CB2 receptor activation on sebocytes reducing the intracellular lipogenesis that produces sebum, and TRPV1 and TRPV4 receptor activation producing anti-proliferative effects on the sebocytes themselves.

 

This sebostatic mechanism is directly relevant to two conditions: acne vulgaris (where sebum overproduction feeds P. acnes growth and inflammation) and seborrheic dermatitis (where sebum dysregulation feeds Malassezia growth). It is also relevant to the oily, clogged-pore dimension of combination skin — not a clinical condition but a cosmetic concern affecting millions.

 

CBD vs Conventional Acne Treatment — Where It Fits

Conventional acne treatment ranges from benzoyl peroxide (antimicrobial) and salicylic acid (comedolytic/anti-inflammatory) to topical retinoids (keratinocyte normalization) and systemic isotretinoin (dramatic sebum reduction, scarring prevention). CBD does not compete with retinoids or isotretinoin for moderate-severe acne — these have decades of evidence and clear mechanisms. CBD's sebostatic and anti-inflammatory mechanisms are most applicable to mild-moderate acne as a standalone approach and as an anti-inflammatory complement to conventional acne treatments for moderate presentations.

 

Atopic Dermatitis (Eczema): The Best-Evidenced CBD Skin Application

Atopic dermatitis is the skin condition with the most developed human evidence for CBD, driven by a2019 randomized controlled trial in the Journal of Dermatological Treatmentexamining a CBD-enriched ointment in AD patients. The study found statistically significant improvements in skin hydration, TEWL (transepidermal water loss — a measure of barrier function), and the SCORAD index (a validated AD severity score) compared to baseline, with no adverse effects reported. This is one of the few RCTs of a topical CBD product in a specific skin condition — and its positive outcome is mechanistically consistent with CBD's CB2 anti-inflammatory and TRPV1 anti-itch mechanisms.

 

The Itch Mechanism: Why CBD's TRPV1 Action Matters for Eczema

Itch in atopic dermatitis is one of the most debilitating features — it disrupts sleep, produces the scratching that mechanically damages the skin barrier, and maintains the itch-scratch cycle that perpetuates the inflammatory state. The itch mechanism in AD involves IL-31 (a Th2 cytokine that activates nerve fibers via TRPV1-adjacent pathways), histamine from mast cell degranulation, and direct nerve fiber sensitization from sustained inflammation. CBD's TRPV1 desensitization reduces the sensitized state of the nerve fibers responsible for itch signaling — addressing the itch independently of the antihistamine mechanism (H1 blockade) that most OTC itch treatments use. This means CBD and antihistamines address itch through different pathways and can work together.

 

Eczema, Stress, and the HPA-Mast Cell Axis: The Oral CBD Connection

Stress is one of the most reliable eczema flare triggers — and the mechanism is specific. Cortisol released under HPA activation has paradoxical effects on mast cells: acute cortisol suppresses mast cell degranulation, but chronic HPA activation (the pattern of sustained stress and burnout) ultimately increases mast cell sensitivity and IgE responsiveness. This HPA-mast cell axis explains why eczema worsens with chronic stress even when topical triggers are avoided. This is where oralCBD Oil adds meaningful value alongside topical treatment: CBD's HPA modulation reduces the chronic cortisol load that sensitizes mast cells, potentially reducing stress-driven eczema flare frequency and severity. For the full HPA mechanism, seeCBD for Anxiety: The Complete Guide.

 

Psoriasis: The Systemic CBD Case

Psoriasis is a T-cell mediated autoimmune condition — not primarily a skin barrier problem like eczema, but a systemic immune dysregulation that manifests most visibly in skin. This distinction matters for CBD route choice: topical CBD addresses the local keratinocyte hyperproliferation and plaque inflammation; oral CBD is needed to address the systemic T-cell and cytokine component that drives recurrent plaque formation.

 

The most directly relevant in vitro evidence for psoriasis comes from studies examining CBD's effect on keratinocyte proliferation. A2007 study in the Journal of Dermatological Science found that CBD inhibited keratinocyte hyperproliferation through CB1 receptor activation — a finding directly relevant to psoriasis's defining pathology (keratinocytes proliferating 4–7× faster than normal to form plaques). CBD's CB2 anti-inflammatory mechanism also targets the T-cell activation and TNF-α production that drive the psoriatic inflammatory cascade.

 

For moderate-to-severe psoriasis, biologic medications targeting IL-17 and IL-23 (secukinumab, ixekizumab, guselkumab) are the most effective treatments and dramatically outperform CBD's mechanisms for disease control. CBD is most appropriately used as: an anti-inflammatory complement to biologics or topical treatments; a management tool for mild psoriasis before or instead of pharmaceutical intervention; or an approach for the psoriatic itch and sleep disruption that biological therapy may not fully address.

 

Topical CBD vs Oral CBD for Skin Conditions: When to Use Each

Topical CBD: Primary for Most Skin Conditions

For localized inflammatory skin conditions, topical CBD application to the affected skin delivers the active compound directly to the CB1/CB2 receptors, TRPV1 channels, and sebaceous glands where it needs to act.PureCraft's CBD Topicals are appropriate for: eczema (apply to affected skin areas after bathing while skin is still slightly damp to maximize penetration); psoriatic plaques (apply to plaque areas 2–3x daily); acne (apply to affected face/back area 1–2x daily as part of skincare routine); seborrheic dermatitis (scalp/T-zone application); and post-herpetic neuralgia skin sensitivity covered in the neuropathy post.

 

Oral CBD Oil: When Systemic Reach Is Needed

OralCBD Oil adds meaningful value for skin conditions when: (1) stress-driven flares are prominent (eczema, psoriasis — the HPA-mast cell axis covered above); (2) the condition is systemic or affects large skin surface areas making topical coverage impractical; (3) sleep disruption from itch or pain is significant (oral CBD's sleep mechanisms operate systemically); or (4) when oral CBD's systemic anti-inflammatory effect is needed for autoimmune skin conditions like psoriasis or dermatitis herpetiformis. For most people with moderate-to-severe inflammatory skin conditions, combining morning oral CBD Oil (15–25mg) for systemic HPA and anti-inflammatory support with topical CBD for local application produces the most comprehensive skin benefit.

 

CBD vs Corticosteroid Cream: The Long-Term Skin Safety Advantage

The most important practical distinction between CBD topical and topical corticosteroid creams is long-term safety for skin integrity. Corticosteroid creams — particularly moderate and potent classes — cause skin atrophy (thinning), telangiectasia (visible blood vessels), hypopigmentation, and topical steroid withdrawal syndrome with prolonged use. These risks limit where they can be applied (not face, not flexures with potent formulations) and for how long. CBD topical has no documented skin atrophy mechanism — CB1/CB2 receptor activation and TRPV1 desensitization do not affect skin structural integrity in the way glucocorticoid receptor activation does. This makes CBD topical appropriate for longer-term use and for sensitive areas where steroid-free maintenance is the goal, which many dermatologists now actively pursue.

 

CBD Alongside Conventional Skin Treatments

 

 

Treatment	Mechanism	Evidence	Key Drawbacks	CBD Alongside or Instead
Topical corticosteroids (hydrocortisone, triamcinolone)	Broad immune suppression via glucocorticoid receptor — reduces T-cell activation, cytokine production, and mast cell response; fast and reliable anti-inflammatory	Strong — first-line for atopic dermatitis, contact dermatitis, psoriasis; decades of evidence	Skin thinning (atrophy) with prolonged use; topical steroid withdrawal syndrome; hypopigmentation; telangiectasia; not for face or flexures with potent steroids	CBD topical does not cause skin atrophy — suitable for long-term use where steroid-free maintenance is the goal; many dermatologists now recommend steroid-free intervals; CBD is appropriate as the steroid-free maintenance option
Topical calcineurin inhibitors (tacrolimus, pimecrolimus)	T-cell calcineurin pathway inhibition — reduces IL-2 and T-cell activation in skin; steroid-free option for sensitive areas (face, neck, flexures)	Strong for atopic dermatitis — FDA-approved; safe for face and skin folds where steroids are limited	Black box warning (theoretical malignancy risk from long-term use — not definitively established); burning sensation on application; prescription-only	CBD topical has no black box warning and no burning on application; appropriate for sensitive skin areas where calcineurin inhibitors are used; evidence base less developed than TCI but mechanism well-characterized
Antihistamines (oral — cetirizine, fexofenadine)	H1 receptor blockade reducing histamine-driven itch and flare response; address IgE/mast cell component of atopic dermatitis	Moderate for itch relief — address histamine component but not the underlying inflammation; drowsiness (first-generation) a significant limitation	First-gen (diphenhydramine): significant sedation; cognitive impairment; second-gen: minimal sedation but limited anti-inflammatory effect	CBD's TRPV1 itch mechanism is different from H1-mediated histamine itch — they address different itch pathways and can be combined; CBD's anti-inflammatory effect is broader than antihistamine's itch-specific action
Moisturizers / barrier repair (ceramide-containing)	Replenish the lipid barrier that atopic dermatitis (filaggrin mutation) disrupts; reduce transepidermal water loss (TEWL); prevent allergen penetration	Strong for atopic dermatitis maintenance — reduces flare frequency; recommended by all major dermatology guidelines	Not anti-inflammatory — barrier repair reduces flare triggers without addressing active inflammation	CBD topical and ceramide moisturizers are complementary — barrier repair reduces the trigger penetration that initiates inflammation; CBD topical addresses the inflammation when it occurs; use both
Dupilumab / biologics (for moderate-severe AD)	IL-4/IL-13 receptor blockade — targets the primary Th2 cytokine pathway driving atopic dermatitis; injectable biologic	Very strong — most effective AD treatment for moderate-severe disease; approval for children 6+ years	Injection (biweekly); cost; conjunctivitis side effect in some patients; requires physician management	CBD topical as adjunct for mild flares between biologic injections; CBD's mechanism does not interfere with IL-4/IL-13 blockade; may allow less frequent rescue steroid use

 

 

How to Use CBD for Skin Conditions: Application Guide

CBD Topical Application Protocol

 

Oral CBD Oil Protocol for Skin Conditions

 

Frequently Asked Questions

 

Can CBD cream help eczema?

Yes — the 2019 Journal of Dermatological Treatment RCT provides the most rigorous human evidence for CBD topical in eczema, showing significant improvements in SCORAD severity score, skin hydration, and transepidermal water loss versus baseline. CBD's mechanism for eczema is specific: CB2 receptor activation on skin immune cells (mast cells, Langerhans cells) reduces the Th2 cytokine production that drives eczema inflammation; TRPV1 desensitization reduces the itch signaling that maintains the itch-scratch cycle; and FAAH inhibition preserves anandamide in skin tissue where eczema's elevated FAAH has depleted it. CBD cream is most appropriately positioned as a steroid-free maintenance option for mild-moderate eczema and as an adjunct to prescribed treatments for more severe presentations.PureCraft's CBD Topicals can be applied 2–3x daily to affected areas, ideally immediately after bathing.

 

Does CBD reduce skin inflammation?

Yes — through two primary mechanisms. CB2 receptor activation on skin immune cells reduces pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) from the mast cells, macrophages, and T cells that drive cutaneous inflammation. FAAH inhibition preserves anandamide in skin tissue, where anandamide acts as a local anti-inflammatory CB1/CB2 agonist. These mechanisms address the inflammatory signaling that produces the redness, swelling, and itch of conditions like eczema, contact dermatitis, and psoriasis. The anti-inflammatory effect is not as potent or as fast as topical corticosteroids — which are more powerful but carry skin atrophy risk with prolonged use — making CBD topical most appropriate as a steroid-free long-term option for mild-moderate inflammation.

 

Is CBD safe on broken eczema skin?

CBD topical is generally considered appropriate for mildly broken eczema skin, but several considerations apply. First, broken skin allows more rapid and complete absorption of topical products — use with a thin, even layer rather than a heavy application to avoid excessive systemic absorption through compromised barrier. Second, for severely broken, weeping, or secondarily infected eczema skin, physician evaluation before applying any new topical product is appropriate — secondary bacterial infection (most commonly Staphylococcus aureus in eczema) requires antibiotic treatment, and topical products may worsen or mask the infection. Third, ensure any CBD topical formulation is fragrance-free and preservative-minimal for use on broken skin — additional ingredients in CBD topicals matter as much as the CBD itself for sensitive and compromised skin.

 

What concentration of CBD topical for eczema?

The human evidence for CBD in eczema used formulations ranging from 1% to 3% CBD concentration in a carrier base. For most inflammatory skin conditions, a concentration of at least 250mg CBD per 1oz (30ml) topical is the practical minimum for meaningful local CB1/CB2 activation. Higher concentrations (500mg+ per oz) may produce stronger local effect, particularly for psoriatic plaques. The carrier base matters as much as the CBD concentration for eczema specifically — emollient, ceramide-rich carriers that support barrier repair are superior to non-emollient carriers for eczema regardless of CBD concentration.

 

Can oral CBD help eczema from inside?

Yes — through a mechanism that is complementary to, not duplicative of, topical CBD. OralCBD Oil addresses the HPA-mast cell axis: chronic stress activates the HPA axis, elevating cortisol in ways that ultimately sensitize mast cells and increase IgE responsiveness — directly contributing to stress-triggered eczema flares. CBD's oral HPA modulation reduces this cortisol load, potentially reducing the frequency of stress-driven flares even when topical triggers are well-managed. Additionally, oral CBD's systemic anti-neuroinflammatory and 5-HT1A effects address the itch-anxiety cycle — eczema itch causes anxiety, anxiety lowers itch threshold, creating a vicious cycle that CBD's systemic mechanisms can interrupt. For people with stress-triggered eczema, the morning oral CBD protocol alongside topical application addresses both the local inflammatory and the systemic stress-trigger dimensions simultaneously.

 

CBD vs cortisone cream for eczema — which is better?

For acute, significant eczema flares, topical corticosteroids produce faster and stronger anti-inflammatory relief than CBD — this is not debatable. Corticosteroids are first-line for a reason. The relevant comparison is in long-term maintenance: topical corticosteroids cannot be used continuously or on facial/flexural skin due to skin atrophy risk. Between flares, dermatologists recommend steroid-free maintenance to allow skin to recover. CBD topical is the most evidence-supported steroid-free maintenance option available — it reduces ongoing low-level inflammation and itch without skin atrophy risk. The optimal approach: corticosteroid cream for active flares (short courses, physician-guided); CBD topical for maintenance between flares; ceramide moisturizer daily throughout.

 

Does CBD help psoriasis too?

Yes — through mechanisms that are well-matched to psoriasis's specific pathology. CBD's CB1 anti-proliferative effect on keratinocytes directly addresses the hyperproliferation that produces psoriatic plaques. Its CB2 anti-inflammatory mechanism reduces the T-cell activation and TNF-α production that drives the autoimmune psoriatic cascade. For mild psoriasis, CBD topical applied to plaques 2–3x daily combined with morning oral CBD Oil for systemic T-cell modulation is a well-reasoned approach. For moderate-to-severe psoriasis — particularly with joint involvement (psoriatic arthritis, covered inCBD for Arthritis) — physician-directed biologic therapy remains the primary intervention and CBD functions as a complement.

 

How long before CBD helps eczema?

For topical CBD applied to eczema lesions: reduction in itch intensity and surface inflammation is typically noticeable within 5–14 days of consistent 2–3x daily application — this is the most acutely perceptible effect and is consistent with the TRPV1 desensitization timeline (the receptor enters a less responsive state with repeated agonist exposure). Measurable improvements in barrier function (TEWL reduction) and SCORAD severity, as documented in the 2019 RCT, were significant at the study endpoint of several weeks. For oral CBD's stress-flare reduction benefit: the HPA recalibration effect requires 4–6 weeks of consistent daily morning dosing. The full combined benefit — local inflammation reduction, itch management, and stress-flare prevention — takes 6–8 weeks of consistently using bothtopical andoral CBD together.

 

The Bottom Line: CBD for Skin Inflammation

The skin has its own endocannabinoid system — and inflammatory skin diseases are characterized by its disruption. CBD's topical application directly engages the CB1/CB2 receptors, TRPV1 channels, and FAAH enzyme in skin tissue, addressing the specific molecular pathways through which eczema, psoriasis, acne, and other inflammatory skin conditions produce their symptoms.

 

The evidence is most developed for atopic dermatitis (the 2019 RCT) and acne (the 2014 JCI sebostatic study), with strong mechanistic support for psoriasis and reasonable observational evidence for seborrheic dermatitis, contact dermatitis, and rosacea. CBD topical's primary advantage over corticosteroid creams is long-term skin safety — no skin atrophy, no steroid withdrawal risk, no restrictions on sensitive areas — making it the most evidence-supported steroid-free maintenance option available.

 

The skin protocol:PureCraft CBD Topicals applied 2–3x daily to affected skin areas (immediately after bathing for eczema; to plaque areas for psoriasis; to acne-affected areas as part of skincare).PureCraft Nano CBD Oil 1000mg (15–25mg sublingual each morning) for stress-triggered flares and systemic anti-inflammatory support. Zero THC,third-party batch-tested COA. Dermatologist evaluation for moderate-severe presentations.

 

Medical Disclaimer |  This article is for informational and educational purposes only. CBD is a supplement, not an FDA-approved treatment for eczema, psoriasis, or any dermatological condition. Persistent or worsening skin conditions warrant professional dermatological evaluation. PureCraft CBD products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary.

 

Related Articles — Conditions Cluster

 

Sources & Citations